Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S385.
doi: 10.21037/atm.2019.12.130.

Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma

Justin A Shaya  1 , Rana R McKay  1
Affiliations
Editorial

Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma

Justin A Shaya et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: RR McKay reports a consultant/advisory role with Bristol Myers Squibb/Pfizer, Exelixis, Janssen, Novartis, and Tempus and institutional research funding from Bayer and Pfizer. JA Shaya has no conflicts of interest to declare.

Comment on

References

    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
    1. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370-85. 10.1016/S1470-2045(19)30413-9 - DOI - PMC - PubMed
    1. Beer L, Hochmair M, Prosch H. Pitfalls in the radiological response assessment of immunotherapy. Memo 2018;11:138-43. 10.1007/s12254-018-0389-x - DOI - PMC - PubMed
    1. Regan MM, Atkins MB, Powles T, et al. Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma. Ann Oncol 2019;30:mdz249.067.
    1. Regan MM, Werner L, Rao S, et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition-a pooled analysis of patients with advanced melanoma. J Clin Oncol 2019;37:3350-8. 10.1200/JCO.19.00345 - DOI - PMC - PubMed